Black Diamond Therapeutics (BDTX) Gains from Investment Securities (2019 - 2021)
Historic Gains from Investment Securities for Black Diamond Therapeutics (BDTX) over the last 3 years, with Q4 2021 value amounting to -$105000.0.
- Black Diamond Therapeutics' Gains from Investment Securities fell 15250.0% to -$105000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was -$90000.0, marking a year-over-year decrease of 10106.21%. This contributed to the annual value of $249000.0 for FY2024, which is N/A changed from last year.
- Per Black Diamond Therapeutics' latest filing, its Gains from Investment Securities stood at -$105000.0 for Q4 2021, which was down 15250.0% from -$5.7 million recorded in Q3 2021.
- In the past 5 years, Black Diamond Therapeutics' Gains from Investment Securities registered a high of $8.3 million during Q3 2020, and its lowest value of -$5.7 million during Q3 2021.
- In the last 3 years, Black Diamond Therapeutics' Gains from Investment Securities had a median value of $16000.0 in 2019 and averaged $766818.2.
- As far as peak fluctuations go, Black Diamond Therapeutics' Gains from Investment Securities surged by 8243000.0% in 2020, and later crashed by 16909.0% in 2021.
- Quarter analysis of 3 years shows Black Diamond Therapeutics' Gains from Investment Securities stood at $26000.0 in 2019, then skyrocketed by 669.23% to $200000.0 in 2020, then plummeted by 152.5% to -$105000.0 in 2021.
- Its Gains from Investment Securities was -$105000.0 in Q4 2021, compared to -$5.7 million in Q3 2021 and $5.7 million in Q1 2021.